TVTX Travere Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1438533 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY49.4%
TTM net income YoY-37.2%
TTM EPS YoY-26.2%
Revenue 3-yr CAGR71.3%
Net income 3-yr CAGR—
Margins
Gross margin98.5%
Operating margin-20.5%
Net margin-18.7%
FCF margin—
EBITDA margin-12.4%
Returns
ROE-252.7%
ROA-17.5%
ROIC (approx.)—
Asset turnover0.94x
Leverage & solvency
Liabilities / assets97.3%
Debt / equity0.00x
Current ratio3.00x
Interest coverage-15.05x
Cash quality & payout
Operating cash flow / net income-1.54x
Accruals ratio-44.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $224.56M | $169.58M | $127.20M | $129.69M | $164.86M | $114.45M | $81.73M | $74.79M |
| Cost of revenue | $2.87M | $2.17M | $1.95M | $2.55M | $1.58M | $1.52M | $4.68M | $2.55M |
| Gross profit | $221.70M | $167.41M | $125.25M | $127.14M | $163.27M | $112.93M | $77.05M | $72.23M |
| R&D expense | $70.30M | $60.28M | $57.09M | $57.87M | $51.89M | $49.36M | $46.89M | $62.07M |
| SG&A expense | $98.41M | $96.11M | $80.25M | $101.69M | $71.05M | $62.58M | $60.41M | $69.50M |
| Operating income | -$68.11M | $3.95M | -$36.91M | -$32.43M | $24.93M | -$12.65M | -$42.67M | -$60.74M |
| Interest expense | $2.14M | $2.13M | $2.30M | $2.30M | $2.75M | $2.85M | $2.86M | $2.82M |
| Pretax income | -$66.93M | -$35.00M | -$36.72M | -$21.07M | $25.71M | -$12.73M | -$41.19M | -$60.34M |
| Income tax | -$5.89M | -$204,000 | -$120,000 | $921,000 | $8,000 | $20,000 | $39,000 | -$72,000 |
| Net income | -$52.34M | -$34.80M | -$37.10M | $2.73M | $25.71M | -$12.76M | -$41.23M | -$60.26M |
| EBITDA | -$62.91M | $8.19M | -$11.70M | -$14.29M | $40.72M | $1.37M | -$29.87M | -$48.65M |
| EPS (basic) | -0.55 | -0.37 | -0.40 | — | 0.29 | -0.14 | -0.47 | — |
| EPS (diluted) | -0.55 | -0.37 | -0.40 | — | 0.28 | -0.14 | -0.47 | — |
| Weighted avg. shares (diluted) | 94.63M | 93.48M | 91.87M | — | 102.62M | 88.95M | 88.36M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $123.54M | $117.73M | $78.36M | $93.03M | $110.93M | $75.15M | $61.90M | $58.53M |
| Short-term investments | $179.83M | $175.91M | $130.59M | $145.38M | $138.66M | — | — | — |
| Receivables | $107.53M | $80.64M | $87.30M | $80.13M | $82.98M | $38.72M | $34.38M | $27.12M |
| Inventory | $43.80M | $40.05M | $37.05M | $36.16M | $37.55M | $37.68M | $38.01M | $41.86M |
| Current assets | $633.45M | $615.14M | $392.68M | $437.56M | $371.11M | $379.57M | $374.17M | $416.70M |
| PP&E, net | $2.72M | $3.23M | $3.63M | $4.02M | $4.32M | $4.56M | $4.85M | $5.34M |
| Goodwill | — | — | — | — | $800,000 | $800,000 | $800,000 | $800,000 |
| Intangibles | $164.11M | $131.52M | $110.04M | $113.87M | $109.44M | $105.61M | $103.82M | $103.97M |
| Total assets | $848.23M | $799.36M | $555.19M | $605.19M | $538.58M | $555.31M | $548.80M | $594.12M |
| Current liabilities | $210.91M | $152.03M | $125.44M | $159.90M | $135.07M | $189.54M | $182.46M | $200.75M |
| Total liabilities | $825.64M | $774.84M | $456.46M | $490.36M | $465.02M | $522.56M | $515.98M | $535.05M |
| Shareholders' equity | $22.58M | $24.52M | $98.73M | $114.83M | $73.56M | $32.75M | $32.82M | $59.08M |
| Shares outstanding | 95.67M | 94.17M | 92.40M | 90.92M | 89.46M | 89.10M | 88.79M | 87.45M |
| Cash flow statement | ||||||||
| Operating cash flow | $109.11M | $58.07M | -$40.37M | $60.68M | $14.32M | $4.98M | -$42.19M | -$35.72M |
| Capital expenditure | — | — | — | — | $140,000 | — | — | — |
| Free cash flow | — | — | — | — | $14.18M | — | — | — |
| Investing cash flow | -$119.63M | -$206.29M | $21.55M | -$104.84M | $86.59M | $4.85M | $41.29M | -$80.31M |
| Financing cash flow | $27.29M | $187.52M | $4.20M | $26.68M | -$65.34M | $1.48M | $3.72M | $139.12M |
| Depreciation & amortization | $5.20M | $4.23M | $25.21M | $18.14M | $15.79M | $14.02M | $12.80M | $12.09M |
| Stock-based compensation | $23.44M | $21.79M | $16.15M | $11.46M | $11.26M | $10.65M | $11.49M | $9.21M |
Free plan shows the latest 8 periods; Pro shows all 69 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.